» Articles » PMID: 39200096

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions

Overview
Journal Biomedicines
Date 2024 Aug 29
PMID 39200096
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes mellitus (DM) and osteoarthritis (OA) are prevalent chronic conditions with shared pathophysiological links, including inflammation and metabolic dysregulation. This study investigates the potential impact of insulin, metformin, and GLP-1-based therapies on OA progression. Methods involved a literature review of clinical trials and mechanistic studies exploring the effects of these medications on OA outcomes. Results indicate that insulin, beyond its role in glycemic control, may modulate inflammatory pathways relevant to OA, potentially influencing joint health. Metformin, recognized for its anti-inflammatory properties via AMPK activation, shows promise in mitigating OA progression by preserving cartilage integrity and reducing inflammatory markers. GLP-1-based therapies, known for enhancing insulin secretion and improving metabolic profiles in DM, also exhibit anti-inflammatory effects that may benefit OA by suppressing cytokine-mediated joint inflammation and supporting cartilage repair mechanisms. Conclusions suggest that these medications, while primarily indicated for diabetes management, hold therapeutic potential in OA by targeting common underlying mechanisms. Further clinical trials are warranted to validate these findings and explore optimal therapeutic strategies for managing both DM and OA comorbidities effectively.

Citing Articles

Recent advances in the management of knee osteoarthritis: a narrative review.

Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O Front Med (Lausanne). 2025; 12:1523027.

PMID: 39906596 PMC: 11790583. DOI: 10.3389/fmed.2025.1523027.


Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions.

Belenichev I, Popazova O, Bukhtiyarova N, Ryzhenko V, Pavlov S, Suprun E Antioxidants (Basel). 2025; 14(1).

PMID: 39857442 PMC: 11760872. DOI: 10.3390/antiox14010108.


Metformin in Antiviral Therapy: Evidence and Perspectives.

Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O Viruses. 2025; 16(12.

PMID: 39772244 PMC: 11680154. DOI: 10.3390/v16121938.

References
1.
Yamaguchi O, Otsu K . Role of autophagy in aging. J Cardiovasc Pharmacol. 2012; 60(3):242-7. DOI: 10.1097/FJC.0b013e31824cc31c. View

2.
Chondronikola M, Yoshino J, Ramaswamy R, Giardina J, Laforest R, Wahl R . Very-low-density lipoprotein triglyceride and free fatty acid plasma kinetics in women with high or low brown adipose tissue volume and overweight/obesity. Cell Rep Med. 2024; 5(1):101370. PMC: 10829791. DOI: 10.1016/j.xcrm.2023.101370. View

3.
Gerrits A, Koekman C, Yildirim C, Nieuwland R, Akkerman J . Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost. 2008; 7(1):198-205. DOI: 10.1111/j.1538-7836.2008.03206.x. View

4.
He M, Lu B, Opoku M, Zhang L, Xie W, Jin H . Metformin Prevents or Delays the Development and Progression of Osteoarthritis: New Insight and Mechanism of Action. Cells. 2022; 11(19). PMC: 9563728. DOI: 10.3390/cells11193012. View

5.
Ristic G, Subota V, Stanisavljevic D, Vojvodic D, Ristic A, Glisic B . Impact of disease activity on impaired glucose metabolism in patients with rheumatoid arthritis. Arthritis Res Ther. 2021; 23(1):95. PMC: 7995801. DOI: 10.1186/s13075-021-02476-0. View